{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:51:17Z","timestamp":1779900677257,"version":"3.53.1"},"reference-count":43,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Calgary Mathison Centre for Mental Health Education and Research Pilot Funding"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Substance use disorders (SUDs) are a major public health challenge, affecting millions of individuals globally and contributing to substantial morbidity and mortality. Individuals with SUDs face numerous barriers to accessing high-quality healthcare, leaving vulnerable populations susceptible to the undertreatment of SUDs. Despite the availability of clinical practice guidelines and effective interventions for SUD, there is a notable gap in the implementation and adherence to evidence-based care.<\/jats:p>\n                    <jats:p>Measuring the quality of care (QoC) is a critical initial step toward enhancing the treatment and services provided to individuals with SUDs. While quality indicators (QIs) for SUD care have been established in various regions, including the USA, Canada and the UK, the application of QIs for the routine measurement of QoC for SUDs is not common. Identifying and characterising the areas of low QoC in SUD management can highlight critical targets for quality improvement initiatives. However, QoC measurement in SUD care is complex, with potentially redundant indicators derived from different sources, each with its own definitions, criteria and data requirements. This scoping review aims to explore the range of QIs that are currently available to assess the QoC for individuals with SUDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The review will follow the Arksey and O\u2019Malley framework and incorporate methods proposed by the Joanna Briggs Institute (JBI) and Levac\n                      <jats:italic>et al<\/jats:italic>\n                      . Reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping review guidelines (PRISMA). Stage 1: the research question will be identified, clarifying the purpose of the scoping review. Stage 2: six academic databases (Cochrane Library, Embase, CINAHL, Medline, APA PsycINFO and Scopus) and grey literature sources will be searched for studies reporting QIs and published from 1990 until 2023. Stage 3: study screening and selection will be completed by two reviewers independently to review titles, abstracts and full texts based on study inclusion criteria. Stage 4: a pilot data charting form has been developed to capture information from each study, including study design, population details, setting, methodology for QI development and reported QIs. Stage 5: data synthesis and consultation will employ thematic analysis and frequency counts to categorise identified QIs within established domains for quality of healthcare. Any discrepancies in data extraction or thematic synthesis will be identified and resolved using a third reviewer when necessary. A consultation exercise using a modified Delphi process will engage experts to prioritise identified QIs, aligning with JBI recommendations for stakeholder involvement in scoping reviews.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and public involvement<\/jats:title>\n                    <jats:p>Patients and the public will not be directly involved in the design or conduct of this scoping review. However, stakeholder consultation, including individuals with lived experience of SUDs, will be incorporated during the Delphi process to prioritise identified QIs for SUD care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval is not necessary for stages 1\u20134 of this scoping review as it will not involve primary data collection. Ethics approval will be obtained from the University of Calgary Health Research Ethics Board prior to the commencement of stakeholder consultation (Stage 5) in January 2025. This scoping review was preregistered on the Open Science Framework. The results of this scoping review will be disseminated through peer-reviewed publications and conference presentations. Findings will be shared with local clinicians through presentations and with the research and clinical community at relevant conferences. This study represents a necessary first step towards establishing routine QoC measurement for SUDs. Results will be used in a stakeholder consensus exercise aimed at identifying key QIs for SUD care in Alberta, Canada, that will guide the future development of continuous QoC measurement using population-based data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-085216","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T06:50:27Z","timestamp":1743231027000},"page":"e085216","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Quality indicators for substance use disorder care: a scoping review protocol"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7189-1669","authenticated-orcid":false,"given":"Ti-Amo DeRuz","family":"Richards","sequence":"first","affiliation":[{"name":"Psychiatry, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kirkham","sequence":"additional","affiliation":[{"name":"Psychiatry, University of Calgary, Calgary, Alberta, Canada"},{"name":"Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8423-3458","authenticated-orcid":false,"given":"Diane","family":"Lorenzetti","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Anderson","sequence":"additional","affiliation":[{"name":"Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"Bahji","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Allami","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Crockford","sequence":"additional","affiliation":[{"name":"Alberta Health Services, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P","family":"Dyson","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumantra Monty","family":"Ghosh","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hodgins","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Messier","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Vik","sequence":"additional","affiliation":[{"name":"Alberta Health Services, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas P","family":"Seitz","sequence":"additional","affiliation":[{"name":"Psychiatry, University of Calgary, Calgary, Alberta, Canada"},{"name":"Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"2025121221471657000_15.3.e085216.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-022-12678-z","article-title":"Polysubstance use poisoning deaths in Canada: an analysis of trends from 2014 to 2017 using mortality data","volume":"22","author":"Konefal","year":"2022","journal-title":"BMC Public Health"},{"key":"2025121221471657000_15.3.e085216.2","unstructured":"Canadian Centre on Substance Use and Addiction (CCSA) . Data from: Canadian drug summary: cocaine. CCSA Repository 2023. Available: https:\/\/www.ccsa.ca\/canadian-drug-summary-cocaine"},{"key":"2025121221471657000_15.3.e085216.3","unstructured":"Canadian Centre on Substance Use and Addiction (CCSA) . Data from: Canadian drug trends. CCSA Repository 2023. Available: https:\/\/www.ccsa.ca\/canadian-drug-trends"},{"key":"2025121221471657000_15.3.e085216.4","unstructured":"Canadian Centre on Substance Use and Addiction (CCSA) . Data from: Canadian drug summary: opioids. CCSA Repository 2023. Available: https:\/\/www.ccsa.ca\/opioids-canadian-drug-summary"},{"key":"2025121221471657000_15.3.e085216.5","unstructured":"Canadian Centre on Substance Use and Addiction (CCSA) . Data from: Canadian drug summary: sedatives. CCSA Repository 2023. Available: https:\/\/www.ccsa.ca\/sedatives-canadian-drug-summary"},{"key":"2025121221471657000_15.3.e085216.6","unstructured":"Canadian Centre on Substance Use and Addiction (CCSA) . Data from: Cannabis (Canadian drug summary). CCSA Repository 2023. Available: https:\/\/www.ccsa.ca\/cannabis-canadian-drug-summary"},{"key":"2025121221471657000_15.3.e085216.7","unstructured":"Canadian Centre on Substance Use and Addiction (CCSA) . Data from: alcohol (Canadian drug summary). CCSA Repository 2023. Available: https:\/\/www.ccsa.ca\/alcohol-canadian-drug-summary"},{"key":"2025121221471657000_15.3.e085216.8","unstructured":"Canada H . Data from: Canadian Alcohol and Drugs Survey (CADS): summary of results for 2019. Health Canada Open Data Repository 2021. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/canadian-alcohol-drugs-survey\/2019-summary.html"},{"key":"2025121221471657000_15.3.e085216.9","doi-asserted-by":"publisher","DOI":"10.1111\/add.12231"},{"key":"2025121221471657000_15.3.e085216.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-019-0227-0","article-title":"Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review","volume":"14","author":"Marchand","year":"2019","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025121221471657000_15.3.e085216.11","unstructured":"CSUCH . Data from: Canadian substance use costs and harms report. Canadian Centre on Substance Use and Addiction (CCSA). 2020. Available: https:\/\/csuch.ca\/publications\/CSUCH-Canadian-Substance-Use-Costs-Harms-Report-2020-en.pdf"},{"key":"2025121221471657000_15.3.e085216.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0242","article-title":"Assessment of Annual Cost of Substance Use Disorder in US Hospitals","volume":"4","author":"Peterson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025121221471657000_15.3.e085216.13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000525268","article-title":"The Treatment of Substance Use Disorders: Recent Developments and New Perspectives","volume":"81","author":"Rosenthal","year":"2022","journal-title":"Neuropsychobiology"},{"key":"2025121221471657000_15.3.e085216.14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2125.2012.04474.x","article-title":"Future pharmacological treatments for substance use disorders","volume":"77","author":"Forray","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025121221471657000_15.3.e085216.15","doi-asserted-by":"crossref","unstructured":"Srivastava AB , Levin FR , Nunes EV , et al . Pharmacological treatment of substance use disorders. In: Tasman A , Riba MB , Alarc\u00f3n RD , eds. Tasman\u2019s psychiatry. Cham: Springer International Publishing, n.d.: 1\u201328.","DOI":"10.1007\/978-3-030-42825-9_140-1"},{"key":"2025121221471657000_15.3.e085216.16","unstructured":"SAMHSA proposes update to federal rules to expand access to opioid use disorder treatment and help close gap in care. 2022. Available: https:\/\/www.samhsa.gov\/newsroom\/press-announcements\/20221213\/update-federal-rules-expand-access-opioid-use-disorder-treatment [Accessed 23 Nov 2023]."},{"key":"2025121221471657000_15.3.e085216.17","unstructured":"Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US) . Early intervention, treatment, and management of substance use disorders. In: Facing addiction in America: the surgeon general\u2019s report on alcohol, drugs, and health. US Department of Health and Human Services, 2016."},{"key":"2025121221471657000_15.3.e085216.18","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21073"},{"key":"2025121221471657000_15.3.e085216.19","unstructured":"Park-Lee E , Lipari RN , Hedden SL , et al . Receipt of services for substance use and mental health issues among adults: results from the 2016 national survey on drug use and health. In: CBHSQ data review. Rockville (MD): Substance Abuse and Mental Health Services Administration (US), 2012."},{"key":"2025121221471657000_15.3.e085216.20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.31128\/AJGP-02-22-6331","article-title":"Lifestyle interventions in the management of substance use disorder","volume":"51","author":"Naren","year":"2022","journal-title":"Aust J Gen Pract"},{"key":"2025121221471657000_15.3.e085216.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12991-021-00374-y","article-title":"Mortality gap and physical comorbidity of people with severe mental disorders: the public health scandal","volume":"20","author":"Fiorillo","year":"2021","journal-title":"Ann Gen Psychiatry"},{"key":"2025121221471657000_15.3.e085216.22","doi-asserted-by":"crossref","unstructured":"Schulte MT , Hser Y-I . Substance Use and Associated Health Conditions throughout the Lifespan. Public Health Rev 2014;35. doi:10.1007\/BF03391702","DOI":"10.1007\/BF03391702"},{"key":"2025121221471657000_15.3.e085216.23","article-title":"Barriers and Facilitators to Substance Use Disorder Treatment: An Overview of Systematic Reviews","volume":"16","author":"Farhoudian","year":"2022","journal-title":"Subst Abuse"},{"key":"2025121221471657000_15.3.e085216.24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajad.13654","article-title":"Trends in racial\/ethnic and geographic disparities in substance use disorders mortality in the United States, 2000-2019","volume":"34","author":"Bhagavathula","year":"2025","journal-title":"Am J Addict"},{"key":"2025121221471657000_15.3.e085216.25","unstructured":"Centers for Disease Control and Prevention (CDC) . Data from: Overdose deaths rise, disparities widen. CDC Repository 2022. Available: https:\/\/www.cdc.gov\/vitalsigns\/overdose-death-disparities\/index.html"},{"key":"2025121221471657000_15.3.e085216.26","unstructured":"StatPearls Publishing . Data from: Diversity and discrimination in health care. StatPearls Repository 2024. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568721\/"},{"key":"2025121221471657000_15.3.e085216.27","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000000663"},{"key":"2025121221471657000_15.3.e085216.28","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181b58882"},{"key":"2025121221471657000_15.3.e085216.29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.15288\/jsads.2019.s18.114","article-title":"Performance Measurement in Mental Health and Addictions Systems: A Scoping Review","volume":"Sup 18","author":"Urbanoski","year":"2019","journal-title":"J Stud Alcohol Drugs Suppl"},{"key":"2025121221471657000_15.3.e085216.30","doi-asserted-by":"crossref","first-page":"109375","DOI":"10.1016\/j.drugalcdep.2022.109375","article-title":"Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada","volume":"233","author":"Nosyk","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2025121221471657000_15.3.e085216.31","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1771","article-title":"Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York","volume":"3","author":"Alegr\u00eda","year":"2022","journal-title":"JAMA Health Forum"},{"key":"2025121221471657000_15.3.e085216.32","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1176\/appi.ps.201600484","article-title":"Association Between Quality Measures and Perceptions of Care Among Patients With Substance Use Disorders","volume":"68","author":"Hepner","year":"2017","journal-title":"Psychiatr Serv"},{"key":"2025121221471657000_15.3.e085216.33","doi-asserted-by":"crossref","unstructured":"Mark TL , Dowd WN , Council CL . Tracking the quality of addiction treatment over time and across states: using the federal government\u2019s \u201csigns\u201d of higher quality. Research Triangle Park: RTI Press, 2020. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559647","DOI":"10.3768\/rtipress.2020.rr.0040.2007"},{"key":"2025121221471657000_15.3.e085216.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2012.07.038"},{"key":"2025121221471657000_15.3.e085216.35","unstructured":"Medicaid . Data from: Adult health care quality measures. Medicaid Repository 2023. Available: https:\/\/www.medicaid.gov\/medicaid\/quality-of-care\/performance-measurement\/adult-and-child-health-care-quality-measures\/adult-health-care-quality-measures\/index.html"},{"key":"2025121221471657000_15.3.e085216.36","unstructured":"Medicaid . Data from: Reducing substance use disorders: quality measures. Medicaid Repository 2023. Available: https:\/\/www.medicaid.gov\/resources-for-states\/innovation-accelerator-program\/functional-areas\/quality-measurement\/reducing-substance-use-disorders-quality-measures\/index.html"},{"key":"2025121221471657000_15.3.e085216.37","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"2025121221471657000_15.3.e085216.38","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69"},{"key":"2025121221471657000_15.3.e085216.39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.11124\/JBIES-22-00123","article-title":"Recommendations for the extraction, analysis, and presentation of results in scoping reviews","volume":"21","author":"Pollock","year":"2023","journal-title":"JBI Evid Synth"},{"key":"2025121221471657000_15.3.e085216.40","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025121221471657000_15.3.e085216.41","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2025121221471657000_15.3.e085216.42","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v11.i4.116"},{"key":"2025121221471657000_15.3.e085216.43","unstructured":"DeRuz T-A , Kirkham J , Seitz D . Data from: A scoping review of quality indicators for substance use disorder care. Open Science Framework (OSF) 2023. Available: https:\/\/osf.io\/75tfx"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-085216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:47:27Z","timestamp":1765604847000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-085216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,29]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-085216"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-085216","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}